



Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

March 9, 2018

BASKING RIDGE, N.J. (March 9, 2018) – Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, today announces that management will be presenting at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) taking place March 15-17, 2018 at the Intercontinental Hotel in Hangzhou, China.

David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present a company overview on Friday, March 16, 2018 at 8:30 a.m. CST.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial. CLBS14, CD34 cell therapy intended as a treatment for coronary microvascular dysfunction and refractory angina, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is formulated specifically for intramuscular administration for the treatment of lower extremity ischemia. A phase 2 study of CLBS12 as a treatment for critical limb ischemia is enrolling in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations. For more information about Caladrius please visit www.caladrius.com.

Contacts:

Investors:

Caladrius Biosciences, Inc.

John Menditto

Executive Director, Investor Relations and Corporate Communications

Phone: +1-908-842-0084

Email: jmenditto@caladrius.com

LHA Investor Relations

Anne Marie Fields

Senior Vice President

Phone: +1-212-838-3777

Email: afields@lhai.com



Source: Caladrius Biosciences, Inc.